Status:
COMPLETED
Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy
Lead Sponsor:
Zagazig University
Conditions:
Effects of Immunotherapy
Eligibility:
All Genders
6-60 years
Phase:
PHASE3
Brief Summary
The aim of the study is: * to evaluate the serum levels of miR-223 and miRNA146a and to assess their correlation with disease severity in allergic rhinitis patients and their role as biomarkers for e...
Detailed Description
Over the last decades the prevalence of allergic disease has steadily been rising and recent figures indicate that in the western world 10-25% of people are affected with allergic diseases ranging fro...
Eligibility Criteria
Inclusion
- Patient consent.
- Patients between 6-60 years old suffering from allergic rhinitis clinically.
- Positive skin prick test
Exclusion
- 1- Chronic inflammatory condition as COPD, tuberculosis, aspergillosis and chronic hepatitis.
- 2- Other allergic diseases as bronchial asthma, allergic conjunctivitis and chronic urticaria 3- Those undergoing chronic treatment with systemic steroids or B- blockers 4- Systemic immunological disorders as systemic lupus erythematous, rheumatoid arthritis and systemic sclerosis.
- 5- Malignancy
Key Trial Info
Start Date :
July 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2022
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04813380
Start Date
July 27 2021
End Date
October 10 2022
Last Update
December 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fatma Zohry Kamel Khater
Zagazig, Egypt, 44511